In this article, we aimed to review the literature on the clinics and management of nonfunctional pancreatic neuroendocrine tumors (NPNET). Pancreatic neuroendocrine tumors (PNET) are rare tumors with a <1/100,000 incidence and constitute approximately 2 to 10% of all pancreatic tumors. Nonfunctional PNETs are difficult to detect at early stages since they have no symptoms. Except those detected accidentally during different diagnoses, the majority of PNETs are detected in the advanced stages, with symptoms related to tumor size or liver metastasis. We reviewed the studies published in the English medical literature through PubMed and summarized the clinical features and current approaches to the treatment and follow-up of the NPNET. The co...
Copyright © 2012 Sven-Petter Haugvik et al. This is an open access article distributed under the Cre...
Neuroendocrine tumor of the pancreas: What is new? Abstract. Neuroendocrine neoplasms are a rare and...
Simple Summary No consensus has been reached regarding whether nonmetastatic nonfunctioning neuroend...
AbstractINTRODUCTIONPancreatic neuroendocrine tumors (PNET) have an incidence of one per 100,000 ind...
The management of pancreatic neuroendocrine tumors (PanNETs) involves classification into non-functi...
ABSTRACT Introduction: Pancreatic neuroendocrine tumors (pNET) correspond to about 3% of all tumor...
Pancreatic neuroendocrine tumors (PNETs) are relatively rare; however, the incidence has increased o...
Pancreatic neuroendocrine tumors (PNETs) are frequent and can be non-functional (NF) in patients wit...
Pancreatic neuroendocrine tumors (pNETs) are rare neoplasms arising from the pancreatic islet of Lan...
BACKGROUND: Pancreatic neuroendocrine tumors (PNET) are rare malignancies frequently diagnosed at a ...
Abstract. There has been a rising trend in the incidence and prevalence of non-functioning pancreati...
Abstract. Pancreatic neuroendocrine tumors (PNETs) are a rare group of neoplasms originating from th...
Pancreatic neuroendocrine tumors (pNETs) are rare and heterogenous tumors and surgery to remove the ...
AbstractIntroductionPancreatic neuroendocrine tumours (pNETs) are rare and the majority of patients ...
Pancreatic neuroendocrine tumors (PNETs) are rare and represent a heterogeneous disease. PNET can be...
Copyright © 2012 Sven-Petter Haugvik et al. This is an open access article distributed under the Cre...
Neuroendocrine tumor of the pancreas: What is new? Abstract. Neuroendocrine neoplasms are a rare and...
Simple Summary No consensus has been reached regarding whether nonmetastatic nonfunctioning neuroend...
AbstractINTRODUCTIONPancreatic neuroendocrine tumors (PNET) have an incidence of one per 100,000 ind...
The management of pancreatic neuroendocrine tumors (PanNETs) involves classification into non-functi...
ABSTRACT Introduction: Pancreatic neuroendocrine tumors (pNET) correspond to about 3% of all tumor...
Pancreatic neuroendocrine tumors (PNETs) are relatively rare; however, the incidence has increased o...
Pancreatic neuroendocrine tumors (PNETs) are frequent and can be non-functional (NF) in patients wit...
Pancreatic neuroendocrine tumors (pNETs) are rare neoplasms arising from the pancreatic islet of Lan...
BACKGROUND: Pancreatic neuroendocrine tumors (PNET) are rare malignancies frequently diagnosed at a ...
Abstract. There has been a rising trend in the incidence and prevalence of non-functioning pancreati...
Abstract. Pancreatic neuroendocrine tumors (PNETs) are a rare group of neoplasms originating from th...
Pancreatic neuroendocrine tumors (pNETs) are rare and heterogenous tumors and surgery to remove the ...
AbstractIntroductionPancreatic neuroendocrine tumours (pNETs) are rare and the majority of patients ...
Pancreatic neuroendocrine tumors (PNETs) are rare and represent a heterogeneous disease. PNET can be...
Copyright © 2012 Sven-Petter Haugvik et al. This is an open access article distributed under the Cre...
Neuroendocrine tumor of the pancreas: What is new? Abstract. Neuroendocrine neoplasms are a rare and...
Simple Summary No consensus has been reached regarding whether nonmetastatic nonfunctioning neuroend...